Shikari® (Q-ENF) Enfortumab ELISA
ENF-FD-PAD
Enzyme immunoassay for quantitative analysis of free Enfortumab in serum and plasma samples.
This kit has been especially developed for the quantitative determination of Enfortumab (Padcev®) in serum and plasma samples between the Cmin and Cmax range of concentrations.
Enfortumab DrugBank ID: DB13007
Patients with advanced, treatment-resistant urothelial malignancies are treated with enfortumab vedotin, an antibody-drug conjugate. It consists of a completely human monoclonal antibody that targets Nectin-4 and monomethyl auristatin E (MMAE), a chemotherapeutic drug that disrupts microtubules, connected via a protease-cleavable bond. It is comparable to another antibody conjugated with MMAE that targets CD-30 rather than Nectin-4, called brentuximab vedotin.
SHIKARI® Enfortumab ELISA has been especially developed for the quantitative analysis of free Enfortumab in serum and plasma samples.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 5 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 1,56 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
